A multicenter, cross‐sectional analysis to assess the safety and usage pattern of brivaracetam in the management of partial‐onset seizure with BAEs—BREEZE study: A post‐hoc analysis
Abstract Objective Brivaracetam (BRV), a third‐generation anti‐seizure medication (ASM) offers strong conformational receptor domain binding, faster blood brain barrier (BBB) permeability and better tolerability making it potential therapeutic option as an initial line or initial line add‐on strateg...
Saved in:
Main Authors: | Arvind Sharma, Krishnaprasad Korukonda, Amit Haldar, Usha Kant Misra, R. V. Anand, Yakshdeep Dave, Girish Kulkarni |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-02-01
|
Series: | Epilepsia Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/epi4.13065 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brivaracetam to Treat Partial Onset Seizures in Adults
by: Dustin Latimer, et al.
Published: (2023-01-01) -
The classification of absence seizures using power-to-power cross-frequency coupling analysis with a deep learning network
by: A.V. Medvedev, et al.
Published: (2025-02-01) -
Incidence and Predictors of Later Epilepsy in Neonates with Encephalopathy: The Impact of Electrographic Seizures
by: Carol M. Stephens, et al.
Published: (2025-02-01) -
Neuropsychological morbidity in the First Seizure Clinic: Prominent mood symptoms and memory issues in epilepsy
by: Remy Pugh, et al.
Published: (2025-02-01) -
ECG‐based epileptic seizure prediction: Challenges of current data‐driven models
by: Sotirios Kalousios, et al.
Published: (2025-02-01)